Derivados de carboxamidina e seu uso no tratamento de doenças vasculares

"DERIVADOS DE CARBOXAMIDINA E SEU USO NO TRATAMENTO DE DOENçAS VASCULARES". A presente invenção refere-se a derivados de carboxamidina para composições farmacêuticas que os contenham e ao uso dos mesmos na preparação de composições farmacêuticas para o tratamento de doenças vasculares. Car...

Full description

Saved in:
Bibliographic Details
Main Authors LASZLO DENES, ZITA JEGESNE CSAKAI, MAGDOLNA BATHONE TOROK, LASZLO UROGDI, EDE MARVANYOS
Format Patent
LanguagePortuguese
Published 28.12.2004
Edition7
Online AccessGet full text

Cover

Loading…
Abstract "DERIVADOS DE CARBOXAMIDINA E SEU USO NO TRATAMENTO DE DOENçAS VASCULARES". A presente invenção refere-se a derivados de carboxamidina para composições farmacêuticas que os contenham e ao uso dos mesmos na preparação de composições farmacêuticas para o tratamento de doenças vasculares. Carboxamidine derivatives (I)-(III) are used for treating or preventing vascular diseases. Carboxamidine derivatives of formula (I)-(III) or their salts are used for treating or preventing vascular diseases. R 1>, R 2>1-6C alkyl (optionally substituted by phenyl), or H, or NR 1>R 2>T; T : 5-7 membered saturated heterocyclyl optionally containing further N or O heteroatoms (optionally substituted by 1 or 2 OH, oxo or benzyl); A : phenyl (optionally substituted by 1 or 2 1-4C alkyl, 1-4C haloalkyl, NO 2or CN), or 5- or 6-membered heteroaryl containing at least one N, O or S and optionally having an N-oxide structure on the N heteroatom; n : 0-2; z : 0 or 1; X : halo or NR 4>R 5>; R 3>-R 5>H or 1-6C alkyl; Y : H, OH, halo or 1-22C acyloxy, and X 1>O, provided that: (1) when R 4>and R 5>are simultaneously H, then Y is not OH; (2) when Y is not halo, then NR 1>R 2>is T, A is N-containing heteroaryl optionally having a N-oxide structure on the N heteroatom and z is 1; (3) when X is halo and Y is hydroxy or acyloxy, then NR 1>R 1>is T; (4) when R 1>and R 2>are 1-6C alkyl (optionally substituted by phenyl), H, and NR 1>R 2>is 5-7 membered saturated heterocyclyl containing N or O, then A is heteroaryl containing O, S or N-containing heteroaryl having a N-oxide structure on the N heteroatom; and (5) when A is phenyl (optionally substituted by 1 or 2 1-4C alkyl, 1-4C haloalkyl, NO 2or halo), or 5- or 6-membered N-containing heteroaryl, then NR 1>R 2>is T. N.B: The formulae (I)-(III) are not shown in the specification. Independent claims are included for the following: (1) new compounds (I), with the further proviso that when Y is H and/or X is NR 4>R 5>, then NR 1>R 2>is T or A is N-containing heteroaryl optionally having an N-oxide structure on the N heteroatom; (2) new compounds (II), with the further proviso that when Y is not halo, then NR 1>R 2>is T and A is N-containing heteroaryl optionally having a N-oxide structure on the N heteroatom, and (3) new compounds (III). ACTIVITY : Vasotropic; Cardiovascular-Gen. In a wounding migration assay in an endothelial cell culture using wounded monolayers of human umbilical vein endothelial cells (HUVEC), results showed that N-[2-chloro-3-(1-piperidinyl)propoxy]-3-nitro-benzimidoyl-chloride hydrochloride gave number of cells/mm 2>at 24 hours of 60, compared to 30 for 5,6-dihydro-5-(1-piperidinyl)-methyl-3-(3-pyridyl)-4H-1,2,4-oxadiazine used as a control. MECHANISM OF ACTION : None given.
AbstractList "DERIVADOS DE CARBOXAMIDINA E SEU USO NO TRATAMENTO DE DOENçAS VASCULARES". A presente invenção refere-se a derivados de carboxamidina para composições farmacêuticas que os contenham e ao uso dos mesmos na preparação de composições farmacêuticas para o tratamento de doenças vasculares. Carboxamidine derivatives (I)-(III) are used for treating or preventing vascular diseases. Carboxamidine derivatives of formula (I)-(III) or their salts are used for treating or preventing vascular diseases. R 1>, R 2>1-6C alkyl (optionally substituted by phenyl), or H, or NR 1>R 2>T; T : 5-7 membered saturated heterocyclyl optionally containing further N or O heteroatoms (optionally substituted by 1 or 2 OH, oxo or benzyl); A : phenyl (optionally substituted by 1 or 2 1-4C alkyl, 1-4C haloalkyl, NO 2or CN), or 5- or 6-membered heteroaryl containing at least one N, O or S and optionally having an N-oxide structure on the N heteroatom; n : 0-2; z : 0 or 1; X : halo or NR 4>R 5>; R 3>-R 5>H or 1-6C alkyl; Y : H, OH, halo or 1-22C acyloxy, and X 1>O, provided that: (1) when R 4>and R 5>are simultaneously H, then Y is not OH; (2) when Y is not halo, then NR 1>R 2>is T, A is N-containing heteroaryl optionally having a N-oxide structure on the N heteroatom and z is 1; (3) when X is halo and Y is hydroxy or acyloxy, then NR 1>R 1>is T; (4) when R 1>and R 2>are 1-6C alkyl (optionally substituted by phenyl), H, and NR 1>R 2>is 5-7 membered saturated heterocyclyl containing N or O, then A is heteroaryl containing O, S or N-containing heteroaryl having a N-oxide structure on the N heteroatom; and (5) when A is phenyl (optionally substituted by 1 or 2 1-4C alkyl, 1-4C haloalkyl, NO 2or halo), or 5- or 6-membered N-containing heteroaryl, then NR 1>R 2>is T. N.B: The formulae (I)-(III) are not shown in the specification. Independent claims are included for the following: (1) new compounds (I), with the further proviso that when Y is H and/or X is NR 4>R 5>, then NR 1>R 2>is T or A is N-containing heteroaryl optionally having an N-oxide structure on the N heteroatom; (2) new compounds (II), with the further proviso that when Y is not halo, then NR 1>R 2>is T and A is N-containing heteroaryl optionally having a N-oxide structure on the N heteroatom, and (3) new compounds (III). ACTIVITY : Vasotropic; Cardiovascular-Gen. In a wounding migration assay in an endothelial cell culture using wounded monolayers of human umbilical vein endothelial cells (HUVEC), results showed that N-[2-chloro-3-(1-piperidinyl)propoxy]-3-nitro-benzimidoyl-chloride hydrochloride gave number of cells/mm 2>at 24 hours of 60, compared to 30 for 5,6-dihydro-5-(1-piperidinyl)-methyl-3-(3-pyridyl)-4H-1,2,4-oxadiazine used as a control. MECHANISM OF ACTION : None given.
Author EDE MARVANYOS
MAGDOLNA BATHONE TOROK
ZITA JEGESNE CSAKAI
LASZLO DENES
LASZLO UROGDI
Author_xml – fullname: LASZLO DENES
– fullname: ZITA JEGESNE CSAKAI
– fullname: MAGDOLNA BATHONE TOROK
– fullname: LASZLO UROGDI
– fullname: EDE MARVANYOS
BookMark eNqFyjsKwkAQBuAttPB1BucCQiBgbH2irdiHMfsLC8lM2NkN3siDeDER7K2-5pu6kahg4i4HxDCwVyMPajje9cld8EGYQIZM2ZREKUVO3EGSfqNXyPvFRgNbk1uOsLkbP7g1LH7O3PJ0vO3PK_Raw3puIEj17lqUxbqqNtvy__gAXYc2NQ
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
Edition 7
ExternalDocumentID BR0306778A
GroupedDBID EVB
ID FETCH-epo_espacenet_BR0306778A3
IEDL.DBID EVB
IngestDate Fri Jul 19 13:05:53 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Portuguese
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_BR0306778A3
Notes Application Number: BR20030306778
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20041228&DB=EPODOC&CC=BR&NR=0306778A
ParticipantIDs epo_espacenet_BR0306778A
PublicationCentury 2000
PublicationDate 20041228
PublicationDateYYYYMMDD 2004-12-28
PublicationDate_xml – month: 12
  year: 2004
  text: 20041228
  day: 28
PublicationDecade 2000
PublicationYear 2004
RelatedCompanies BIOREX KUTATO ES FEJLESZTO RT
RelatedCompanies_xml – name: BIOREX KUTATO ES FEJLESZTO RT
Score 2.6096041
Snippet "DERIVADOS DE CARBOXAMIDINA E SEU USO NO TRATAMENTO DE DOENçAS VASCULARES". A presente invenção refere-se a derivados de carboxamidina para composições...
SourceID epo
SourceType Open Access Repository
Title Derivados de carboxamidina e seu uso no tratamento de doenças vasculares
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20041228&DB=EPODOC&locale=&CC=BR&NR=0306778A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdR3LTsMwzBoDATcYoPHOAfVWQd_doUK0XTWQ9lA10G5T0mRiB5pp6YA_4kP4MdxqBS67RUlkOVb8jO0A3AjHyhjaGXonc23d5uiwMmZ0dNOZGYJarstpWeDcH7i9Z_tp4kwa8FrXwlR9Qj-q5ojIURnye1HJ68VfECuucivVLZvjlLxPxkGs1d6xbZimr8Vh0B0N42GkRVEQptogDSrT2PMftmAbjWiv5IXuS1jWpCz-K5TkAHZGCCsvDqGxKFqwF9X_rrVgt79-7sbhmvPUETzGeFXeKZeKcEEyumTyk77NUfNQIogSK7JSkuSSlN1maRnyk-VGLkX-_UUVqTNOhTqG66Q7jno64jT9Pf40TGvkrRNo5jIXbSCGRTn1nYwJCw2aO-rPkKoetzrC91B-zU6hvQnK2ealc9ivGxma_gU0i-VKXKLSLdhVRa8fCTqI4A
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdR3LTsMwzBoDMW4wQOO5HFBvFfTdHSpE200b7KVpoN2mpE3FDjTT0gF_xIfwY7jVClx2i5LIcqz4GdsBuOGWETG0M9RWZJuqGaPDypjWUnUr0Tg1bDumeYHzYGh3n83HmTWrwGtZC1P0Cf0omiMiR0XI71khr5d_QaywyK2Ut2yBU-K-M_VCpfSOTU3XXSX0vfZ4FI4CJQg8f6IMJ15hGjvuww7sooHt5LzQfvHzmpTlf4XSOYS9McJKsyOoLLM61ILy37U67A82z9043HCePIZeiFflncZCkpiTiK6Y-KRvC9Q8lHAi-ZqspSCpIHm3WZqH_ES-MRY8_f6ikpQZp1yeQLPTngZdFXGa_x5_7k9K5I1TqKYi5Q0gmkFj6loR4wYaNHfUTZCqTmy0uOug_ErOoLENyvn2pSbUutNBf97vDZ8u4KBsaqi7l1DNVmt-hQo4Y9cF7X4AoC6L0w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Derivados+de+carboxamidina+e+seu+uso+no+tratamento+de+doen%C3%A7as+vasculares&rft.inventor=LASZLO+DENES&rft.inventor=ZITA+JEGESNE+CSAKAI&rft.inventor=MAGDOLNA+BATHONE+TOROK&rft.inventor=LASZLO+UROGDI&rft.inventor=EDE+MARVANYOS&rft.date=2004-12-28&rft.externalDBID=A&rft.externalDocID=BR0306778A